Lamotrigine in the treatment of binge-eating
disorder with obesity: a randomized, placebo-controlled monotherapy trial
International Clinical Psychopharmacology, 04/21/09
Guerdjikova AI et al. - Lamotrigine was associated with a numerically greater amount of weight loss (1.17 vs. 0.15 kg) and significant reductions in fasting levels of glucose, insulin, and triglycerides.
Methods- Fifty-one outpatients with BED by Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria, and obesity were randomized to receive either lamotrigine (N=26) or placebo (N=25) in a 16-week, double-blind, flexible-dose study.
- Lamotrigine (236�150 mg/day) and placebo had similar rates of reduction of weekly frequency of binge-eating episodes and binge days, weight and BMI, measures of eating pathology, obsessive-compulsive symptoms, impulsivity, and global severity of illness.
No comments:
Post a Comment